Arfon G M T Powell1, Paul G Horgan, Joanne Edwards. 1. Unit of Experimental Therapeutics, Institute of Cancer Science, College of Medical, Veterinary and Life of Sciences, University of Glasgow, McGregor Building, Western Infirmary, Glasgow, UK. arfon.powell@glasgow.ac.uk
Abstract
INTRODUCTION: Loss of human leucocyte antigen (HLA) class I expression has been implicated in tumour progression and metastasis; however, studies reporting its relationship with long-term survival are few in number with conflicting reports. The aim of this review was to assess the prognostic value of HLA class I expression in gastrointestinal cancer. METHODS: Major electronic databases, including Medline, Embase, Cochrane Library and Pubmed were searched for original studies. Two independent reviewers assessed each study against inclusion and exclusion criteria. All data were specific to gastrointestinal cancer surgery. RESULTS: Fourteen original studies were included in this present review. In oesophageal cancer, reduced expression of HLA-A, HLA-B, HLA-C and HLA-G were associated with poorer survival. However, in gastric and colorectal cancer, the prognostic value of HLA-A, HLA-B, HLA-C and HLA-G remains conflicting. Antibody use and reporting methodology was different between all 14 studies examined. CONCLUSION: Variability in antibody use makes it difficult to validate HLA class I expression as an independent prognostic marker in GI cancer. Consensus guidelines, incorporating heavy and light chain antibodies, are required with further studies on HLA class I expression being performed to validate its prognostic value.
INTRODUCTION: Loss of human leucocyte antigen (HLA) class I expression has been implicated in tumour progression and metastasis; however, studies reporting its relationship with long-term survival are few in number with conflicting reports. The aim of this review was to assess the prognostic value of HLA class I expression in gastrointestinal cancer. METHODS: Major electronic databases, including Medline, Embase, Cochrane Library and Pubmed were searched for original studies. Two independent reviewers assessed each study against inclusion and exclusion criteria. All data were specific to gastrointestinal cancer surgery. RESULTS: Fourteen original studies were included in this present review. In oesophageal cancer, reduced expression of HLA-A, HLA-B, HLA-C and HLA-G were associated with poorer survival. However, in gastric and colorectal cancer, the prognostic value of HLA-A, HLA-B, HLA-C and HLA-G remains conflicting. Antibody use and reporting methodology was different between all 14 studies examined. CONCLUSION: Variability in antibody use makes it difficult to validate HLA class I expression as an independent prognostic marker in GI cancer. Consensus guidelines, incorporating heavy and light chain antibodies, are required with further studies on HLA class I expression being performed to validate its prognostic value.
Authors: Jonathan A D Simpson; Ahmad Al-Attar; Nicholas F S Watson; John H Scholefield; Mohammad Ilyas; Lindy G Durrant Journal: Gut Date: 2010-07 Impact factor: 23.059
Authors: Andrew B C Crumley; James J Going; Mustafa Hilmy; Sumanta Dutta; Claire Tannahill; Margaret McKernan; Joanne Edwards; Robert C Stuart; Donald C McMillan Journal: Ann Surg Oncol Date: 2011-03-16 Impact factor: 5.344
Authors: Matthias Kloor; Christina Becker; Axel Benner; Stefan M Woerner; Johannes Gebert; Soldano Ferrone; Magnus von Knebel Doeberitz Journal: Cancer Res Date: 2005-07-15 Impact factor: 12.701
Authors: Frank M Speetjens; Elza C de Bruin; Hans Morreau; Eliane C M Zeestraten; Hein Putter; J Han van Krieken; Maaike M van Buren; Monique van Velzen; N Geeske Dekker-Ensink; Cornelis J H van de Velde; Peter J K Kuppen Journal: Cancer Immunol Immunother Date: 2007-09-15 Impact factor: 6.968
Authors: Jacky T Yeung; Ronald L Hamilton; Koji Ohnishi; Maki Ikeura; Douglas M Potter; Marina N Nikiforova; Soldano Ferrone; Regina I Jakacki; Ian F Pollack; Hideho Okada Journal: Clin Cancer Res Date: 2013-02-11 Impact factor: 12.531
Authors: C C Engels; A Charehbili; C J H van de Velde; E Bastiaannet; A Sajet; H Putter; E A van Vliet; R L P van Vlierberghe; V T H B M Smit; J M S Bartlett; C Seynaeve; G J Liefers; P J K Kuppen Journal: Breast Cancer Res Treat Date: 2015-01-24 Impact factor: 4.872